New combination acne treatment

Epiduo (adapalene 0.1% + benzoyl peroxide 2.5%) is a new anti-acne gel containing two agents with complementary mechanisms of action.

Adapalene (Differin) is thought to modulate cellular differentiation and keratinisation; it also has anti-inflammatory activity. Benzoyl peroxide has ketatolytic, exfoliative, sebostatic and antimicrobial properties.

Two 12-week, randomised, double-blind studies of Epiduo were conducted in a total of 2185 patients. The gel produced greater reductions in lesion counts and had higher success rates (proportion of patients rated ‘clear' or ‘almost clear') than either of the active components alone, or placebo (gel vehicle).

View Epiduo drug record

Further information: Galderma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

SGLT2 inhibitors backed for cardiovascular prevention in draft NICE guidance

SGLT2 inhibitors backed for cardiovascular prevention in draft NICE guidance

SGLT2 inhibitors should be considered as first-line...